Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chi

来源 :中华医学杂志英文版 | 被引量 : 0次 | 上传用户:binics
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background::Recent cardiovascular outcome trials (CVOTs) changed the therapeutic strategy of guidelines for type 2 diabetes. We compared the characteristics of patients from real-world hospital settings with those of participants in recent pragmatic randomized trials.Methods::This electronic medical record (EMR)-based retrospective observational study investigated the data of patients with diabetes from inpatient and outpatient settings in West China Hospital of Sichuan University from January 1, 2011, to June 30, 2019. We identified patients meeting the inclusion criteria of a pragmatic randomized trial (EMPA-REG OUTCOME) based on EMRs and compared their baseline characteristics with those of the trial participants. The cutoff for the clinical significance of each characteristic was set as its minimal clinically important difference based on expert consultation.Results::We included 48,257 inpatients and 36,857 outpatients with diabetes and found that 8389 (17.4%) inpatients and 2646 (7.2%) outpatients met the inclusion criteria for the EMPA-REG OUTCOME trial. Compared with the trial population, the realworld inpatients meeting the eligibility criteria of the EMPA-REG OUTCOME had similar age, blood pressure, and lipid profiles but comprised of fewer males, metformin users, anti-hypertensive drug users, and aspirin users, and had a lower body mass index. The group of outpatients meeting the eligibility criteria had fewer males, similar age, fewer metformin users, fewer insulin users, fewer anti-hypertensive drug users, and fewer aspirin users compared with the trial population.Conclusions::The trial population in EMPA-REG OUTCOME represents only a small portion of patients with diabetes from the inpatient and outpatient departments of a Chinese tertiary medical center. Evidence localization in different clinical settings and validation are essential to enabling extrapolation of the results from CVOTs in patients with diabetes to Chinese clinical practice.“,”Background::Recent cardiovascular outcome trials (CVOTs) changed the therapeutic strategy of guidelines for type 2 diabetes. We compared the characteristics of patients from real-world hospital settings with those of participants in recent pragmatic randomized trials.Methods::This electronic medical record (EMR)-based retrospective observational study investigated the data of patients with diabetes from inpatient and outpatient settings in West China Hospital of Sichuan University from January 1, 2011, to June 30, 2019. We identified patients meeting the inclusion criteria of a pragmatic randomized trial (EMPA-REG OUTCOME) based on EMRs and compared their baseline characteristics with those of the trial participants. The cutoff for the clinical significance of each characteristic was set as its minimal clinically important difference based on expert consultation.Results::We included 48,257 inpatients and 36,857 outpatients with diabetes and found that 8389 (17.4%) inpatients and 2646 (7.2%) outpatients met the inclusion criteria for the EMPA-REG OUTCOME trial. Compared with the trial population, the realworld inpatients meeting the eligibility criteria of the EMPA-REG OUTCOME had similar age, blood pressure, and lipid profiles but comprised of fewer males, metformin users, anti-hypertensive drug users, and aspirin users, and had a lower body mass index. The group of outpatients meeting the eligibility criteria had fewer males, similar age, fewer metformin users, fewer insulin users, fewer anti-hypertensive drug users, and fewer aspirin users compared with the trial population.Conclusions::The trial population in EMPA-REG OUTCOME represents only a small portion of patients with diabetes from the inpatient and outpatient departments of a Chinese tertiary medical center. Evidence localization in different clinical settings and validation are essential to enabling extrapolation of the results from CVOTs in patients with diabetes to Chinese clinical practice.
其他文献
目的 分析2010~2019年西藏自治区肺结核患者人群分布特征,为结核病预防和控制重点人群提供依据.方法 收集2010~2019年西藏疾病预防控制系统结核病患者管理信息系统和传染病报告
目的 探讨智慧家医模式应用于在职2型糖尿病患者管理的作用.方法 选择100例在职2型糖尿病患者作为本次研究主体,根据随机分配的方式将这100例患者分为两组,对照组(50例)接受
目的了解外周末梢全血与血清降钙素原(PCT)水平的相关性和一致性,探讨末梢全血PCT检测在儿科感染领域中的应用价值。方法横断面研究,对2018年3月至2019年2月在11所儿童专科医院出生28 d以上的1 898例患儿同时采集的末梢全血和静脉血清,分别检测PCT水平,根据文献资料和临床对静脉血清PCT正常参考值及其临床意义分组。采用χ2检验和方差分析进行组间比较,定量数值Pearson相关分析法进
本文报道了左肺下叶恶性血管周上皮样细胞瘤伴脑转移1例。患者女,49岁,胸部CT表现为左肺下叶背段团块状软组织密度影,密度不均,内见多发 囊状低密度影,增强扫描呈明显不均匀强化,囊性部分未见强化。颅脑MRI表现为左侧小脑半球占位并周围明显水肿。病理诊断:左肺下叶恶性血管周上皮样细胞瘤伴脑转移。
Background::Although increasing abnormal expression of circular RNAs (circRNAs) has been revealed in various cancers, there were a small number of studies about
本文报道1例50岁女性左肾嗜酸性实性和囊性肾细胞癌的影像表现。病灶呈类圆形囊实性,边界清晰,CT平扫实性成分呈等密度,增强肾皮质期及实质期持续渐进性强化,排泄期强化减退,强化
合成MRI是一种新兴的定量弛豫技术,能够实现一次扫描同时获得多种定量弛豫图,直接用于组织定量分析。对数据进行后处理分析,能实现脑组织分割、容积定量和髓鞘容积测定等功能。基于测得的弛豫值,能够合成多种对比加权图像,包括一些少用的扫描序列,为临床提供更多有价值的诊断信息。近年来,合成MRI技术逐渐成熟,已成功应用于全身多个部位。本文主要对合成MRI技术的临床应用进展进行综述。
本文报道不典型肺巨细胞一例。患者男,63岁,因体检发现肺占位1周就诊,4年内因多关节肿痛伴晨僵,多次就诊我院。2019年11月11日胸部CT平扫及增强检查示左肺下叶胸膜下病灶呈纵向附壁生长,见偏心性坏死,增强后病灶明显强化,见截断的小肺动脉分支。术后病理确诊为肺巨细胞癌。
患儿男,18个月,产前MRI及超声提示胎儿小脑及脑干发育不良。产后患儿行头颅MRI检查,可见脑桥腹侧扁平,局部略凹陷,被盖部明显突入第四脑室,形似“帽状”或“喙状”,中脑-脑桥结合部(菱脑峡)前后径变窄,小脑上脚及下脚变薄,双侧小脑中脚体积明显缩小,菱脑峡层面呈“臼齿”样改变。诊断为脑桥被盖“帽状”发育不良。幼儿期该病的影像表现有特征性,产前检查发现后颅窝小脑及脑干发育不良时也应将其作为鉴别诊断。
人工智能(AI)技术正逐渐应用于心血管影像领域。本文将着重介绍AI技术在计算机辅助诊断和临床研究方面的应用,即分别从技术应用层面及心血管疾病临床研究方面,介绍目前AI技术在心血管影像领域中的最新进展。最后,对AI技术目前存在的一些共性问题,以及其在心血管影像领域应用过程中存在的一些问题进行总结,并对AI技术在心血管影像领域未来的发展进行展望。